Reviewing Tilray (TLRY) and Its Rivals

Tilray (NASDAQ: TLRY) is one of 33 publicly-traded companies in the “Medicinals & botanicals” industry, but how does it compare to its competitors? We will compare Tilray to related companies based on the strength of its analyst recommendations, valuation, risk, dividends, institutional ownership, profitability and earnings.

Risk & Volatility

Tilray has a beta of 2.92, meaning that its stock price is 192% more volatile than the S&P 500. Comparatively, Tilray’s competitors have a beta of 2.57, meaning that their average stock price is 157% more volatile than the S&P 500.

Institutional & Insider Ownership

10.4% of Tilray shares are held by institutional investors. Comparatively, 21.6% of shares of all “Medicinals & botanicals” companies are held by institutional investors. 16.8% of Tilray shares are held by insiders. Comparatively, 25.8% of shares of all “Medicinals & botanicals” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Tilray and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Tilray -259.60% -77.77% -21.45%
Tilray Competitors -1,150.45% -258.05% -48.97%

Valuation and Earnings

This table compares Tilray and its competitors revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Tilray $166.98 million -$321.17 million -2.92
Tilray Competitors $219.25 million -$99.48 million 2.20

Tilray’s competitors have higher revenue and earnings than Tilray. Tilray is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Tilray and its competitors, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tilray 1 12 2 0 2.07
Tilray Competitors 135 358 403 14 2.33

Tilray currently has a consensus price target of $12.73, indicating a potential upside of 158.16%. As a group, “Medicinals & botanicals” companies have a potential upside of 110.71%. Given Tilray’s higher probable upside, research analysts clearly believe Tilray is more favorable than its competitors.

Summary

Tilray competitors beat Tilray on 8 of the 13 factors compared.

Tilray Company Profile

Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Nanaimo, Canada.

Receive News & Ratings for Tilray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray and related companies with MarketBeat.com's FREE daily email newsletter.